Suppression of Hepatitis B Virus Production and Inflammatory Response in vitro and in vivo by Mormodica charantia Compound EMCDO


  •  Chi-I Chang    
  •  Chiy-Rong Chen    
  •  Yo-Chia Chen    
  •  Kuei-Wen Cheng    
  •  Bo-Wei Lin    
  •  Yun-Wen Liao    
  •  Wen-Ling Shih    

Abstract

Eight compounds were purified from Mormodica charanti, and their chemical structures were determined in this study. Their anti-HBV and anti-inflammation activities were investigated. Compound EMCDO exhibited the most efficient effect in terms of reducing HBV surface antigen, e antigen and viral DNA levels in HBV particles or surface antigen-producing cells 2.2.15 and PLC/PRF/5, respectively. Tumor suppressor p53 played a significant role in EMCDO-mediated anti-HBV effects. Pretreatment with EMCDO prevented 2.2.15 cells-induced tumor formation in a nude mice subcutaneous model. The anti-HBV and anti-tumor activities of EMCDO were better than those of oltipraz, an inhibitor of HBV transcription. EMCDO reduced the proinflammatory cytokines and mediators in LPS-treated RAW264.7 cells in a dose-dependent manner. The LPS-upregulated phosphorylation level of Ika was reduced in the presence of EMCDO. The transcription activity of NF-kB was increased in cells treated with EMCDO. Utilization of a mouse ear edema model further confirmed the activity of EMCDO against TPA-elicited inflammation.



This work is licensed under a Creative Commons Attribution 4.0 License.